Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Bronchiolitis Obliterans Syndrome × belumosudil × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7 ibrutinib 5 Dasatinib 3 ruxolitinib 2 ofatumumab 2 nilotinib 2 bosutinib 2 asciminib 2 Oxycodone 2 Naloxone 2 KW-2478 2 Imatinib Mesylate 2 obinutuzumab 1 mocetinostat 1 milatuzumab 1 fenebrutinib 1 canakinumab 1 belumosudil 1 baricitinib 1 axatilimab 1 abexinostat 1 Vision, Ocular 1 Sofosbuvir 1 Saline Solution 1 Rituximab 1 Ribavirin 1 RO6839921 1 Panobinostat 1 KD025 1 Hsp90 inhibitor KU757 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Sanofi

Phase 2 Terminated

159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡